My Companies
Notification
Account
Log Out
Login
Natco filed draft offer for rights issue aggregating up to Rs 13,000 million. Proceeds earmarked Rs 8,105m for debt repayment, Rs 1,100m for R&D over FY27-28, balance for acquisitions and general corporate purposes. Promoters intend to subscribe. Context: structures pending fundraising evaluation.
Natco Pharma Approves Rights Issue Of Up To ₹1,300 Crore
Natco Pharma Explores ₹2,000 Crore Capital Raise Alongside Q1 Results
Natco Pharma Gets US FDA Tentative Approval For Olaparib Generic
Natco Pharma Board Approves ₹1,069 Crore Adcock Ingram Stake Hike To 49%